Inhibition of interleukin-1 type I receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide.

[1]  C. Dinarello,et al.  The interleuldn-1 family: 10 years of discovery’ , 2004 .

[2]  R. Wagner.  Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[3]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Dayer,et al.  Interleukin-1, tumor necrosis factor and their specific inhibitors. , 1994, European cytokine network.

[5]  C. Dinarello,et al.  The biological properties of interleukin-1. , 1994, European cytokine network.

[6]  S. Dower,et al.  Interleukin-1 receptors. , 1994, European cytokine network.

[7]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[8]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. , 1994, The Journal of biological chemistry.

[9]  C. Dinarello,et al.  Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. , 1994, Cancer research.

[10]  J. Wands,et al.  Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. , 1994, The Journal of biological chemistry.

[11]  C. Bennett,et al.  Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. , 1994, Journal of immunology.

[12]  A. Fauci,et al.  Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Schotanus,et al.  Human recombinant interleukin-1 receptor antagonist prevents adrenocorticotropin, but not interleukin-6 responses to bacterial endotoxin in rats. , 1993, Endocrinology.

[14]  D. Eizirik,et al.  Treatment With an Interleukin-1 Receptor Antagonist Protein Prolongs Mouse Islet Allograft Survival , 1993, Diabetes.

[15]  H. Towbin,et al.  Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. , 1993, Clinical and experimental rheumatology.

[16]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[17]  R. Thompson,et al.  Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits , 1993, Infection and immunity.

[18]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[19]  C. Dinarello.  Blocking interleukin-1 in disease. , 1993, Blood purification.

[20]  Stanley T. Crooke,et al.  Antisense Research and Applications , 1993 .

[21]  C. Dinarello.  Modalities for reducing interleukin 1 activity in disease. , 1993, Immunology today.

[22]  J. Norton,et al.  Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. , 1993, The Journal of surgical research.

[23]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[24]  B. Sokolov,et al.  Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. , 1993, Biochemistry.

[25]  C. Bennett,et al.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.

[26]  S. Dower,et al.  Interleukin-1 represents a new modality for the activation of extracellular signal-regulated kinases/microtubule-associated protein-2 kinases. , 1991, The Journal of biological chemistry.

[27]  R. Thompson,et al.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. , 1991, Immunology today.

[28]  L. Mahan,et al.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. , 1991, The Journal of clinical investigation.

[29]  S. Freier,et al.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. , 1991, The Journal of biological chemistry.

[30]  S. Dower,et al.  IL-1 induces rapid phosphorylation of the IL-1 receptor. , 1989, Journal of immunology.

[31]  W. Rychlik,et al.  A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA. , 1989, Nucleic acids research.

[32]  S. Mizel,et al.  The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. , 1987, Journal of immunology.

[33]  A. Krieg,et al.  Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. , 1994, Antisense research and development.

[34]  W. Arend.  Interleukin-1 receptor antagonist. , 1993, Advances in immunology.

[35]  P. Iversen,et al.  Systemic human antisense therapy begins. , 1992, Antisense research and development.

[36]  S. Crooke.  Therapeutic Applications of Oligonucleotides , 1992, Bio/Technology.

[37]  B. Dolnick.  Antisense agents in cancer research and therapeutics. , 1991, Cancer investigation.